Eye On The Prize: For $8.7 Billion, Valeant Will Acquire Bausch & Lomb
This article was originally published in The Pink Sheet Daily
As with its Medicis buyout in 2012, Valeant is acquiring another company to serve essentially as a therapeutic division within the specialty pharma the Canadian firm is cobbling together from relentless M&A activity. Buying B&L will increase Valeant’s eye care holdings substantially.
You may also be interested in...
Valeant’s Pearson Is Out, As Hunt Begins For A CEO To Right The Wrongs
Valeant has begun the search for a new CEO, who will be charged with turning around the troubled company and likely divesting some assets. The company also calls out former CFO Howard Schiller for “improper conduct.”
Sanofi Should Take Note: Insiders Might Just Make Better CEOs
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
India’s Sun Pharma Reported Bid For Bausch & Lomb And Meda Raises Hopes For Bigger Buyouts
Sun Pharma has been increasingly linked to a potential global deal in the branded and specialty segments. With former Teva CEO Israel Makov as Sun’s chairman, and robust earnings continuing to pour in, a deal may be just around the corner.